drugset
drugset / Trial / NCT04589403

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403 ↗

Phase 1 Completed 14 enrolled Op-T LLC
RandomizedParallel-groupTriple-blindOther

Summary

This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.

Timeline

Start
2021-02-18
Primary completion
2021-09-27
Completion
2021-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject OPT101 Peptide 0.16 mg/kg Intravenous
Subject OPT101 Peptide 0.42 mg/kg Intravenous
Subject OPT101 Peptide 1.1 mg/kg Intravenous
Subject OPT101 Peptide 2.8 mg/kg Intravenous
Subject OPT101 Peptide 7.3 mg/kg Intravenous

Indications

No indication recorded.